HavaH Therapeutics is developing androgen therapies for breast disease by utilizing the innate breast-tissue-specific hormone/immune interface. HavaH Therapeutics lead product delivers a unique androgen product to effect a beneficial tissue specific alteration in estrogen:androgen ratio and reduce breast tissue autoimmune inflammation. HavaH Therapeutics is dedicated to developing androgenic products for women, initially targeting rare breast disease where autoimmunity is the underlying mechanism of the pathogenesis e.g. granulomatous and peri-ductal mastitis.